Albireo Pharma’s PFIC Therapy; Lupin’s T...

Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback caused Cyclerion to switch its focus to IW-6463 and to treat central nervous system diseases....

Schizophrenia is over a hundred years old term; and ever since it has kept the scientific communities scratching their head. Obvious psychotic symptoms, other neurodegenerative mimics, underdiagnosis, and sometimes even overdiagnosis, Schizophrenia is a complex disorder in itself, affecting approximately 20 million...

Designing a universal flu vaccine by focusing on the immune system  A universal flu vaccine that can foster protection to people against any influenza strain is considered a goal in flu research as it could spare scientists from the often erroneous process of predicting the circulating strains each year and...

Opioid overdose is a severe health problem. As per the WHO, worldwide, around 0.5 million deaths are attributable to drug use. More than 70% of these deaths are related to opioids, with more than 30% of those deaths caused by overdose. Considered as a safe option to relieve pain, the Opiates have been in use for th...

Marijuana also referred to as cannabis, is always in debate for its benefits and detriments. In some countries, it is legal while in some countries it is considered as a recreational and harmful product, and its cultivation, trafficking, possession, and ingesting can lead to a fine or even imprisonment. However, al...

J&J commences COVID-19 vaccine phase 3 Johnson & Johnson has begun a 60,000-subject phase 3 evaluation of its COVID-19 vaccine. The trial will enroll participants in the U.S. and other countries with a high incidence of COVID-19 to generate data to bolster emergency use authorization early next year. ...